National
Chairmen sending mixed signals on ‘Don’t Ask’
President Obama is being pressured to include a “Don’t Ask, Don’t Tell” repeal as part of his upcoming defense budget request to Congress, but the response from two key Democrats to such a proposal could hinder any change in the law.
Two lawmakers with considerable sway over defense matters — and whether a repeal will initially be part of the fiscal year 2011 defense budget — are House Armed Services Committee Chairman Ike Skelton (D-Mo.) and Senate Armed Services Committee Chairman Carl Levin (D-Mich.).
As leaders of the congressional committees that handle defense matters, Skelton and Levin get first crack at determining what’s included in the defense budget after the president sends his base bill to Congress in February. The lawmakers can make changes to the president’s request in their chairman’s marks to the legislation before the rest of Congress takes action.
So if Obama includes “Don’t Ask, Don’t Tell” repeal as part of his defense budget request, it’s possible for either Skelton or Levin to strike the language from the bill if they don’t want it there.
“You could make the argument that the chairman’s mark is the most vulnerable moment for what happens with repeal legislation this year,” said Aaron Belkin, director of the Palm Center, a think-tank on gays in the military at the University of California, Santa Barbara.
Some advocates, including Belkin, are questioning whether Levin and Skelton would retain Obama’s request to lift the ban on open service in the U.S. armed forces as part of their chairman’s marks for the defense budget.
Belkin was particularly skeptical about Levin’s willingness to let repeal go forward because of the senator’s history on “Don’t Ask, Don’t Tell.”
“Levin has been a huge problem on this issue,” Belkin said. “Who the hell knows where Levin is personally, but I would say that very few people in the United States have done more to obstruct the service of openly gay troops than Carl Levin.”
Belkin took issue with Levin’s abandoned plan to hold hearings last year on “Don’t Ask, Don’t Tell.” Those hearings never took place.
“I think it’s been now three times that he’s announced that the Senate would hold hearings on ‘Don’t Ask, Don’t Tell,’ Belkin said. “He just made the announcement again that they’re going to have hearings. But why were there no hearings last year despite the repeated announcements?”
A Senate Armed Services Committee spokesperson didn’t respond to the DC Agenda’s request for comment on whether Levin would allow repeal language to remain in his chairman’s mark for the defense budget.
Last week, Levin announced the Senate Armed Services Committee would hold hearings on gays in the military by the end of this month and that Chairman of the Joint Chiefs of Staff Adm. Michael Mullen and Defense Secretary Robert Gates would testify.
Matt Canter, spokesperson for Sen. Kirsten Gillibrand (D-N.Y.), said the hearing is scheduled for next week. Although not a member of the Senate Armed Services Committee, Gillibrand has been a strong advocate for repealing “Don’t Ask, Don’t Tell” since she took office last year.
Belkin also criticized Levin for not finding a Republican co-sponsor for a Senate repeal bill, which some say has prevented the introduction of the legislation in that chamber.
C. Dixon Osburn, former head of the Servicemembers Legal Defense Network, said Levin has gone on record several times as noting that he supports repeal of the ban, but acknowledged Levin is “somebody who’s very much a consensus builder within the Senate Armed Services Committee.”
“So if it’s not percolating up in the Senate Armed Services Committee, he’s going to be more reluctant even as he believes that the law should repealed, and right now you don’t have the bubbling up within the Senate Armed Services Committee,” Osburn said.
Although there’s concern among “Don’t Ask, Don’t Tell” opponents about Levin, Skelton has been the more vocal of the two lawmakers in supporting the existing ban on open service in the military. According to The Hill newspaper, Skelton said last week during an interview on C-SPAN’s “Newsmakers” that he is “personally not for changing the law.”
Still, both Belkin and Osburn said they aren’t as concerned about Skelton’s position on “Don’t Ask, Don’t Tell” as they are with Levin.
“It’s not helpful to have the chairman of House Armed Services oppose you, but I don’t think he’s the center of gravity in the House any more,” Belkin said. “All that said, it is sad … Chairman Skelton stands for firing gay Arabic linguists during a national security emergency. I’m not quite sure why that makes him feel safer.”
Osburn said the only moderation that he’s seen from Skelton on “Don’t Ask, Don’t Tell” is his willingness in the past couple years to have House hearings on the issue.
“And I think that the hope is if there’s a strong majority in the House supporting repeal, that he will accede,” Osburn said. “I’m less sanguine since he’s announced that he supports delay, but I think that Congressman [Patrick] Murphy is such a strong leader on this, and he’s developed such support around this in the House, that it is still a good possibility that this can move forward in the House.”
Lara Battles, spokesperson for the House Armed Services Committee, said she couldn’t say whether Skelton would include repeal language in his chairman’s mark for the defense budget, which she said would be public in May.
In 2008, the House Armed Services personnel subcommittee held the first hearing on “Don’t Ask, Don’t Tell” in 15 years. Aaron Hunter, spokesperson for Rep. Susan Davis (D-Calif.), chair of the subcommittee, said the panel intends to hold another hearing, although a date hasn’t been set.
If either Levin or Skelton removes repeal language from the defense legislation, lawmakers could reinsert the provision through an amendment.
The Advocate reported last week that gay Rep. Barney Frank (D-Mass.) said it doesn’t matter whether the Pentagon includes repeal in the budget request because lawmakers have the votes in the House to put the language in the legislation.
“I do not think it matters what the Pentagon says,” Frank was quoted as saying. “We will get the votes without it, I think.”
Some activists also were confident the House could muster enough support to pass an amendment that would lead to overturning the law. Still, whether there are 60 votes in the Senate to overcome a filibuster was in question.
Osburn said the Senate is a “much more difficult prospect” than the House because there isn’t a strong leader advocating for repeal in that chamber.
“Now that said, there’s a still a possibility,” he said. “There are still enough senators who support repeal that if the House moves on this, one or more senators could get together and ensure the amendment is attached to DOD authorization bill as well.”
If the House version of the bill has repeal language and the Senate version doesn’t, lawmakers would have to hash out whether repeal would be included in the final bill during conference committee — another potential point where the repeal strategy could fail.
Osburn said “it’s a possibility” that repeal language could survive conference, but that would depend on who congressional leaders appoint as conferees.
“The effort that the LGBT community would need to push for is to ensure that the conference committee includes people who are going to be supportive of this and will leave it in,” he said.
The White House
‘Trump Rx’ plan includes sharp cuts to HIV drug prices
President made announcement on Friday
President Donald Trump met with leaders from some of the world’s largest pharmaceutical companies at the White House on Friday to announce his new “Trump Rx” plan and outline efforts to reduce medication costs for Americans.
During the roughly 47-minute meeting in the Roosevelt Room, Trump detailed his administration’s efforts to cut prescription drug prices and make medications more affordable for U.S. patients.
“Starting next year, American drug prices will come down fast, furious, and will soon be among the lowest in the developed world,” Trump said during the meeting. “For decades, Americans have been forced to pay the highest prices in the world for prescription drugs by far … We will get the lowest price of anyone in the world.”
Trump signed an executive order in May directing his administration “to do everything in its power to slash prescription drug prices for Americans while getting other countries to pay more.”
“This represents the greatest victory for patient affordability in the history of American health care, by far, and every single American will benefit,” he added.
Several pharmaceutical executives stood behind the president during the announcement, including Sanofi CEO Paul Hudson, Novartis CEO Vas Narasimhan, Genentech CEO Ashley Magargee, Boehringer Ingelheim (USA) CEO Jean-Michel Boers, Gilead Sciences CEO Dan O’Day, Bristol Myers Squibb General Counsel Cari Gallman, GSK CEO Emma Walmsley, Merck CEO Robert Davis, and Amgen Executive Vice President Peter Griffith.
Also in attendance were Health and Human Services Secretary Robert F. Kennedy Jr., Commerce Secretary Howard Lutnick, Centers for Medicare and Medicaid Services Administrator Mehmet Oz, and Food and Drug Administration Commissioner Marty Makary.
Under the Trump Rx plan, the administration outlined a series of proposed drug price changes across multiple companies and therapeutic areas. Among them were reductions for Amgen’s cholesterol-lowering drug repatha from $573 to $239; Bristol Myers Squibb’s HIV medication reyataz from $1,449 to $217; Boehringer Ingelheim’s type 2 diabetes medication jentadueto from $525 to $55; Genentech’s flu medication xofluza from $168 to $50; and Gilead Sciences’ hepatitis C medication epclusa from $24,920 to $2,425.
Additional reductions included several GSK inhalers — such as the asthma inhaler advair diskus 500/50, from $265 to $89 — Merck’s diabetes medication januvia from $330 to $100, Novartis’ multiple sclerosis medication mayzent from $9,987 to $1,137, and Sanofi’s blood thinner plavix from $756 to $16. Sanofi insulin products would also be capped at $35 per month’s supply.
These prices, however, would only be available to patients who purchase medications directly through TrumpRx. According to the program’s website, TrumpRx “connects patients directly with the best prices, increasing transparency, and cutting out costly third-party markups.”
Kennedy spoke after Trump, thanking the president for efforts to lower pharmaceutical costs in the U.S., where evidence has shown that drug prices — including both brand-name and generic medications — are nearly 2.78 times higher than prices in comparable countries. According to the Pharmaceutical Research and Manufacturers of America, roughly half of every dollar spent on brand-name drugs goes to entities that play no role in their research, development, or manufacturing.
“This is affordability in action,” Kennedy said. “We are reversing that trend and making sure that Americans can afford to get the life-saving solutions.”
Gilead CEO Dan O’Day also spoke about how the restructuring of drug costs under TrumpRx, combined with emerging technologies, could help reduce HIV transmission — a virus that, if untreated, can progress to AIDS. The LGBTQ community remains disproportionately affected by HIV.
“Thank you, Mr. President — you and the administration,” O’Day said. “I think this objective of achieving the commitment to affordability and future innovation is extraordinary … We just recently launched a new medicine that’s only given twice a year to prevent HIV, and we’re working with Secretary Kennedy and his entire team, as well as the State Department, as a part of your strategy to support ending the epidemic during your term.
“I’ve never been more optimistic about the innovation that exists across these companies and the impact this could have on America’s health and economy,” he added.
Trump interjected, asking, “And that’s working well with HIV?”
“Yes,” O’Day replied.
“It’s a big event,” Trump said.
“It literally prevents HIV almost 100 percent given twice a year,” O’Day responded.
A similar anti-HIV medication is currently prescribed more than injectable form mentioned by O’Day. PrEP, is a medication regimen proven to significantly reduce HIV infection rates for people at high risk. Without insurance, brand-name Truvada can cost roughly $2,000 per month, while a generic version costs about $60 per month.
Even when medication prices are reduced, PrEP access carries additional costs, including clinic and laboratory fees, office visits, required HIV and sexually transmitted infection testing, adherence services and counseling, and outreach to potentially eligible patients and providers.
According to a 2022 study, the annual total cost per person for PrEP — including medication and required clinical and laboratory monitoring — is approximately $12,000 to $13,000 per year.
The TrumpRx federal platform website is now live at TrumpRx.gov, but the program is not slated to begin offering reduced drug prices until January.
The White House
EXCLUSIVE: Democracy Forward files FOIA lawsuit after HHS deadnames Rachel Levine
Trans former assistant health secretary’s name changed on official portrait
Democracy Forward, a national legal organization that works to advance democracy and social progress through litigation, policy and public education, and regulatory engagement, filed a lawsuit Friday in federal court seeking to compel the U.S. Department of Health and Human Services to release information related to the alteration of former Assistant Secretary for Health Adm. Rachel Levine’s official portrait caption.
The lawsuit comes in response to the slow pace of HHS’s handling of multiple Freedom of Information Act requests — requests that federal law requires agencies to respond to within 20 working days. While responses can take longer due to backlogs, high request volumes, or the need for extensive searches or consultations, Democracy Forward says HHS has failed to provide any substantive response.
Democracy Forward’s four unanswered FOIA requests, and the subsequent lawsuit against HHS, come days after someone in the Trump-Vance administration changed Levine’s official portrait in the Hubert H. Humphrey Building to display her deadname — the name she used before transitioning and has not used since 2011.
According to Democracy Forward, HHS “refused to release any records related to its morally wrong and offensive effort to alter former Assistant Secretary for Health Admiral Rachel Levine’s official portrait caption.” Levine was the highest-ranking openly transgender government official in U.S. history and served as assistant secretary for health and as an admiral in the U.S. Public Health Service Commissioned Corps from 2021 to 2025.
Democracy Forward President Skye Perryman spoke about the need to hold the Trump-Vance administration accountable for every official action, especially those that harm some of the most targeted Americans, including trans people.
“The question every American should be asking remains: what is the Trump-Vance administration hiding? For an administration that touts its anti-transgender animus and behavior so publicly, its stonewalling and silence when it comes to the people’s right to see public records about who was behind this decision is deafening,” Perryman said.
“The government’s obligation of transparency doesn’t disappear because the information sought relates to a trailblazing former federal official who is transgender. It’s not complicated — the public is entitled to know who is making decisions — especially decisions that seek to alter facts and reality, erase the identity of a person, and affect the nation’s commitment to civil rights and human dignity.”
“HHS’s refusal to respond to these lawful requests raises more serious concerns about transparency and accountability,” Perryman added. “The public has every right to demand answers — to know who is behind this hateful act — and we are going to court to get them.”
The lawsuit also raises questions about whether the alteration violated federal accuracy and privacy requirements governing Levine’s name, and whether the agency improperly classified the change as an “excepted activity” during a lapse in appropriations. By failing to make any determination or produce any records, Democracy Forward argues, HHS has violated its obligations under federal law.
The case, Democracy Forward Foundation v. U.S. Department of Health and Human Services, was filed in the U.S. District Court for the District of Columbia. The legal team includes Anisha Hindocha, Daniel McGrath, and Robin Thurston.
The Washington Blade reached out to HHS, but has not received any comment.
The lawsuit and four FOIA requests are below:
The White House
Empty seats, canceled shows plague Kennedy Center ahead of Trump renaming
It would take an act of Congress to officially rename the historic music venue, despite the Trump-appointed board’s decision.
The board of the Kennedy Center in Washington, D.C., voted to rename it the Trump-Kennedy Center, according to the White House Press Office.
White House Press Secretary Karoline Leavitt announced the decision in a post on X Thursday, thanking the president for his work on the cultural center “not only from the standpoint of its reconstruction, but also financially, and its reputation.”
Speaking to reporters later that day at the White House, Trump said he was “surprised” and “honored” by the board’s vote.
“This was brought up by one of the very distinguished board members, and they voted on it, and there’s a lot of board members, and they voted unanimously. So I was very honored,” he said.
Earlier this year, GOP Rep. Mike Simpson of Idaho introduced an amendment that would have renamed the building after first lady Melania Trump, later saying she had not been aware of his efforts prior to the amendment’s public introduction.
Despite the board’s vote (made up of Trump-appointed loyalists), the original laws guiding the creation of the Kennedy Center during the Eisenhower, Kennedy, and Johnson administrations explicitly prohibit renaming the building. Any change to its name would require an act of Congress.
Trump has exerted increasing control over the center in recent months. In February, he abruptly fired members of the Kennedy Center’s board and installed himself as chair, writing in a Truth Social post at the time, “At my direction, we are going to make the Kennedy Center in Washington D.C., GREAT AGAIN.”
In that post, Trump specifically cited his disapproval of the center’s decision to host drag shows.
He later secured more than $250 million from the Republican-controlled Congress for renovations to the building.
Since Trump’s takeover, sales of subscription packages are said to have declined, and several touring productions — including “Hamilton” — have canceled planned runs at the venue. Rows of empty seats have also been visible in the Concert Hall during performances by the National Symphony Orchestra.
“The Kennedy Center Board has no authority to actually rename the Kennedy Center in the absence of legislative action,” House Minority Leader Hakeem Jeffries told reporters.
For decades, the Kennedy Center has hosted performances by LGBTQ artists and companies, including openly queer musicians, choreographers, and playwrights whose work helped push LGBTQ stories into the cultural mainstream. Those artists include the Gay Men’s Chorus of Washington, Harvey Fierstein, and Tennessee Williams.
In more recent years, the center has increasingly served as a space for LGBTQ visibility and acceptance, particularly through Pride-adjacent programming and partnerships.
That legacy was on display at this year’s opening production of Les Misérables, when four drag performers — Tara Hoot, Vagenesis, Mari Con Carne, and King Ricky Rosé — attended in representation of Qommittee, a volunteer network uniting drag artists to support and defend one another amid growing conservative attacks.
“We walked in together so we would have an opportunity to get a response,” said Tara Hoot, who has performed at the Kennedy Center in full drag before. “It was all applause, cheers, and whistles, and remarkably it was half empty. I think that was season ticket holders kind of making their message in a different way.”
The creation of the Kennedy Center is outlined in U.S. Code, which formally designates the institution as the John F. Kennedy Center for the Performing Arts.
As a result, it appears unlikely that Congress will come together to pass legislation allowing the historic venue to be renamed.
‘Trump Rx’ plan includes sharp cuts to HIV drug prices
Rehoboth’s Blue Moon is for sale but owners aim to keep it in gay-friendly hands
Comings & Goings
Advocates say MTG bill threatens trans youth, families, and doctors
EXCLUSIVE: Democracy Forward files FOIA lawsuit after HHS deadnames Rachel Levine
LGBTQ Democrats say they’re ready to fight to win in 2026
Brian Footer suspends campaign for Ward 1 D.C. Council seat
Far-right José Antonio Kast elected Chile’s next president
Lighting candles in a time of exhaustion
In real estate, trust the process
-
Politics2 days agoLGBTQ Democrats say they’re ready to fight to win in 2026
-
District of Columbia2 days ago
Brian Footer suspends campaign for Ward 1 D.C. Council seat
-
Chile4 days ago
Far-right José Antonio Kast elected Chile’s next president
-
Opinions2 days ago
Lighting candles in a time of exhaustion
